Viatris (VTRS) has just put fresh numbers on the table, reporting third quarter 2026 results that show a larger net loss even as full year revenue guidance edges higher.
Recent trading suggests investors are still weighing that story. The share price has retreated about 1.3% on the day but logged a 15.5% 90 day share price return and a 52.3% year to date share price return, while total shareholder return over the past year is 94.3%. This points to strong longer term momentum despite shorter term volatility around Viatris news flow and guidance tweaks.
Scan how Viatris compares to other healthcare stocks showing strong price trends and balance sheet support by reviewing the curated 42 high quality undervalued stocks today.
Viatris has reported a wider quarterly loss alongside a very strong 1 year share price run. That mix of weaker earnings and firm pricing raises a simple question: Are you paying for business progress or pure sentiment in today’s valuation?
Most Popular Narrative: 5% Undervalued
Against a last close of $18.97, the most followed narrative pegs Viatris at a fair value of $20.00, implying a modest discount that rests on specific product and cost actions rather than broad optimism.
Expansion of higher-value branded and complex products such as the Gwyn Lo contraceptive patch and the planned Creon dose escalation label update in Europe is expected to shift Viatris' mix away from lower-margin oral generics and support revenue growth and gross margin resilience.
Continued build-out of a non-opioid pain portfolio, including the FDA-accepted NDA for fast-acting meloxicam with a December 27, 2026 PDUFA date and the planned acquisition of Pacira BioSciences with EXPAREL and ZILRETTA, positions Viatris to add new branded revenue streams and potentially lift earnings quality.
See why 49 investors see Viatris as 5% undervalued.
Result: Fair Value of $20.00 (UNDERVALUED)
Still, heavy reliance on mature off patent products and ongoing remediation issues at Indore and Nashik could pressure Viatris and test this undervalued narrative.
Find out about the key risks to this Viatris narrative.
Next Steps
Mixed messages around Viatris can cut both ways, so move quickly, review the data, and pressure test the story against the 3 key rewards and 1 important warning sign.
Ready for more Viatris style ideas?
If Viatris has your attention, do not stop at a single ticker. Broaden your watchlist with a few focused screens that match your risk and income goals.
- Target resilient balance sheets by scanning companies in the list of solid balance sheet and fundamentals (24 results) and cut down the time spent worrying about excessive leverage.
- Hunt for potential mispricings by reviewing the 42 high quality undervalued stocks and see which businesses the market may be underrating today.
- Combine potential returns and income by checking the 6 dividend fortresses and identify higher yielding stocks that prioritize capital preservation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com